# EDGAR Filing Document

**Accession Number:** 0001676163
**File Stem:** 0001213900-25-050789
**Filing Date:** 2025-6
**Character Count:** 32361
**Document Hash:** 3b310fb7781ad7b81f55ac9877b33fd8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-050789.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001213900-25-050789

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 45

**CONFORMED PERIOD OF REPORT**: 20250603

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SS Innovations International, Inc.
- **CENTRAL INDEX KEY:** 0001676163
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 473478854
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42615
- **FILM NUMBER:** 251019577

**BUSINESS ADDRESS:**
- **STREET 1:** 1600 SE 15TH STREET
- **STREET 2:** #512
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33316
- **BUSINESS PHONE:** (954) 478-1410

**MAIL ADDRESS:**
- **STREET 1:** 1600 SE 15TH STREET
- **STREET 2:** #512
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33316

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AVRA Medical Robotics, Inc.
- **DATE OF NAME CHANGE:** 20160601

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 3, 2025**

**<u>SS INNOVATIONS INTERNATIONAL, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Florida** | **001-42615** | **47-3478854** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **05, 3rd Floor** **, iLabs Info Technology Centre<br> Udyog Vihar, Phase III,<br> Gurugram, Haryana, India** | **122016** |
| Address of Principal Executive Office *(Street and Number)* | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>+91 73375 53469</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each Class</u> <u>Trading Symbol</u> <u>Name of each exchange on which registered</u> <br> Common Stock SSII The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this "**Report**"), the terms "**SSi**," "**the Company**," "**we**," "**us**" and "**our**" refer to SS Innovations International, Inc. and its subsidiaries.

**Item 7.01. Regulation FD Disclosure.**

Attached hereto is an updated Company Presentation (the "**Presentation**"), which SSi intends to use in communications to shareholders and the investment community.

A copy of the Presentation is attached to this Report as **Exhibit 99.1**.

The information set forth in this **Item 7.01** and in the Presentation included as **Exhibit 99.1** to this Report, are deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), or otherwise subject to the liabilities of that Section. The information set forth in this **Item 7.01** and in Presentation included as **Exhibit 99.1** to this Report, including without limitation, information accessed through the link set forth above, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

***<u>Forward-Looking Statements</u>***:

This Report may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "anticipate," "assume," "believe," "estimate," "expect," "will," "intend," "may," "plan," "project," "should," "could," "seek," "designed," "potential," "forecast," "target," "objective," "goal," or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SSi's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company's actual results to differ materially from those presented in its forward-looking statements are set forth in the Company's Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company's subsequent reports. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to SSi's operations, results of operations, growth strategy and liquidity.

**Item 9.01 Financial Statements and Exhibits.**

(d) *Exhibits*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1\* | [June 2025 Company Presentation](ea024444101ex99-1_ssinno.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Furnished but not filed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: June 3, 2025 | **SS INNOVATIONS INTERNATIONAL, INC.** | **SS INNOVATIONS INTERNATIONAL, INC.** |
|  | By: | /s/ Sudhir Srivastava |
|  |  | Sudhir Srivastava, M.D. |
|  |  | Chairman and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

We Build Advanced, Affordable and Accessible Surgical Robotic Solutions SS Innovations International, Inc. Company Presentation June 2025 Nasdaq: SSII

![](ex99-1_002.jpg)

Forward - Looking Statements This Presentation contains forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended and Section 21 E of the Securities Exchange Act of 1934 , as amended . These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by our forward - looking statements . Examples of forward - looking statements include projected financial information, statements of our plans and objectives for future operations and statements concerning proposed new products and services . In some cases, you can identify forward - looking statements by the use of terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential" and other comparable terminology . Although we believe that the expectations reflected in the forward - looking statements are reasonable, we cannot guarantee future results, performance or achievements . Actual events or results may differ materially . We undertake no obligation to update any of the forward - looking statements after the date of this Presentation to conform them to actual results . Please refer to the risk factors described in the "Risk Factors" section and other sections included in the Company's Annual Report on Form 10 - K, Quarterly Reports on Form 10 - Q and other filings with the SEC . No Offering of Securities No offer is made by this Presentation to invest in the Company or to purchase any of its securities . Any offer to make such an investment or purchase and such investment or purchase will be made only pursuant to definitive offering documentation furnished by the Company . 2© 2025 SS INNOVATIONS INTERNATIONAL, INC. Forward - Looking Statements

![](ex99-1_003.jpg)

Snapshot of SS Innovations • We develop innovative, differentiated surgical robotic technologies, highlighted by our: • proprietary, gold - standard surgical robotic system, "SSi Mantra 3" ; • comprehensive suite of surgical instruments , which support a variety of surgical procedures, including robotic cardiac surgery ; and • AI - and XR - driven imaging, training and simulation platform . • Our vision: to continuously improve and deploy our technologically - advanced , cost - effective surgical robotic systems, while maintaining affordability and accessibility for the benefit of a larger segment of patients globally. • We are backed by a team of leading surgical robotics experts and seasoned medical technology executives. • We are a rapidly growing American company with Indian roots, expanding globally and preparing for our strategic entry into Europe and the United States . 4,000+ Multi - Specialty Surgeries 93 SSI Mantra Systems Installed 75 Hospitals 100+ Validated Surgical Procedures 9 Surgical Specialities 200+ Robotic Cardiac Surgeries 16 Tele Surgeries 0 Complications Injuries Mortalities 3© 2025 SS INNOVATIONS INTERNATIONAL, INC. Estimated data up to April 30, 2025, except for surgeries and systems installed as of June 2025

![](ex99-1_004.jpg)© 2025 SS INNOVATIONS INTERNATIONAL, INC. 4 Snapshot of SS Innovations (Continued) Headquarters Gurugram, India US Office New York, NY Employees (4/15/25) 378 Year Founded 2019 Year Merged with Avra Medical 2023 Ticker SSII Exchange Nasdaq Shares Out (5/13/25) 193.6 mm Recent Price (5/29/25) $6.03 Market Cap (5/29/25) $1.2 bn Insider Ownership (4/14/25) 76.5% 1585 1191 589 213 213 123 54 50 5 General Surgery Cardiac Thoracic Urology Colorectal Head & Neck Gynecology Gastrointestinal Breast and Plastic 4,023 Total Surgeries to Date 1 1 Estimated data as of May 2025 $5.9 $20.6 2023 2024 Annual Revenue (in US millions) 24 78 As of 3/31/24 As of 3/31/25 Systems Installed (cumulative data)

![](ex99-1_005.jpg)© 2025 SS INNOVATIONS INTERNATIONAL, INC. 5 Investment Highlights and Agenda • Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology • Advanced, Surgical Robotics Technology Platform Validated Clinically and Commercially • Differentiated Product Offering , Including Optimal Cost - Effectiveness and Cardiac Surgery Capabilities • Large and Growing Addressable Market with Favorable Industry Tailwinds • World - Class R&D and Manufacturing Facilities to Support Growth • Stronghold in India, Global Expansion Underway with Near - Term Catalysts Anticipated in the EU and US • Early Innings of Exponential Sales Growth, Expanding Margins and Increasing Mix of Recurring Revenue • Strategy to Deliver Long - Term, Sustainable Growth

![](ex99-1_006.jpg)© 2025 SS INNOVATIONS INTERNATIONAL, INC. 6 Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology Sudhir Srivastava, MD, Founder, Chairman, CEO & Director • Robotic Cardiac Surgeon • Pioneered many of the world's first robotic cardiac procedures • 40+ years of surgical experience; trained 350+ clinical teams • 1,400+ robotic cardiac surgeries • Trained 350+ clinical teams • University of British Colombia, University of Chicago, Alliance Hospital • Owns 117,158,445 shares, or 58.9% of SSII shares outstanding 1 Frederic Moll, MD, Vice - Chairman • Former Chief Development Officer, J&J Medical Devices • Founder, Intuitive Surgical, Hansen Medical, Auris Health • Founder Partner, Sonder Capital Management • Board Member, Procept Biorobotics, Neptune Medical, Moon Surgical • Former Board Member, Shockwave Medical, Restoration Robotics, Intersect ENT • Widely regarded as the "Father of Surgical Robotics" • Owns 20,335,045 shares, or 10.2% of SSII shares outstanding 1 1 As of 4/14/2025

![](ex99-1_007.jpg)

Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology Vishwajyoti Srivastava, MD, Chief Executive Officer - APAC • Columbia University • International College of Robotic Surgeons Arvind Palaniappan, Interim Chief Financial Officer • Chartered Accountant, Institute of Chartered Accountants, England and Wales • Principal, Trogon Consulting • Various Executive Positions, Accenture Solutions (India) Barry Cohen, COO - Americas • Co - Founder, CEO and Director, Avra Medical Robotics • Former Director and President, Synalloy Corp. • Former Chairman of the Board, Wolverine Technologies, Inc. Tim Paul Adams, Board Member • Regional Operating Officer, Ascension • Former Regional CEO, Tenet Healthcare • Chairman, Tennessee Hospital Association Somashekhar SP, MD, Board Member • Robotic Surgeon • Global Director, Aster International Institute of Oncology Dr. Mylswamy Annadurai, Board Member • Former Director, Indian Space Research Organization (ISRO) 7© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_008.jpg)

Advanced Surgical Robotics Technology Platform SSi Mantra 3 Intellectual Property Granted 5 Utility patents 30 Design patents Estimated data up to March 31, 2025 8© 2025 SS INNOVATIONS INTERNATIONAL, INC. 69 Filed patent applications Trademarks Filed: 124; Registered: 53 Improved Patient Experience Reduced Variabilities Lower Per Procedure Costs

![](ex99-1_009.jpg)

Advanced Surgical Robotics Technology Platform SSi Mantra 3 - Surgical Command Center Ergonomic Open - Faced Console Large 3D 4K Monitor Large 2D Touch Monitor for System Controls and DICOM access Lightweight Magnetic Hand Controls Design Head Tracking Safety Feature Digital Ergonomics Control Tele Surgery and Tele Proctoring Enabled 9© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_010.jpg)

Advanced Surgical Robotics Technology Platform SSi Mantra 3 – Patient Side Robotic Arm Carts Modular Robotic Carts Freedom of Patient Docking 3/4/5 Patient Cart Connectivity Absolute Stability Parking Locks Smaller Individual Cart Footprint Advanced Touch Screen Controls Multi - Specialty Use Including Cardiac Surgery 10© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_011.jpg)

Advanced Surgical Robotics Technology Platform SSi Mantra 3 – Vision Cart Large 3D 4K Monitor for OR Staff Inbuilt Multimedia Recording, Playback and Streaming Articulating Endoscope and Camera System Pre - Operative Guidance Software UPS Backup E - Stop Safety Features Standard 5 Robotic Arms Connectivity Control Box 11© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_012.jpg)

Advanced Surgical Robotics Technology Platform SSi Mudra – Multi Specialty Robotic Instruments 7 Degrees of Freedom Articulating Robotic Instruments 10 Use Life Cycle per Instrument 20+ Cardiac Specialty Instruments 40+ Types of Instruments Novel Instrument: Automated Coronary Anastomotic Connector\* Novel Instrument: Multi - Fire Clip Applier\* Advanced Instruments: Selicut Harmonic Advanced Instruments: ExpertSeal Vessel Sealer Advanced Instruments: Anastoflex Stapler \* Under Development 12© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_013.jpg)

Advanced Surgical Robotics Technology Platform SSi Mudra – Cardiac Robotic Instruments 20+ Cardiac Specialty Instruments\* Robotic Cardiac Surgery Potential Only company in the world actively advocating for robotic cardiac surgery Untapped market potential in automated coronary artery bypass surgery 190+ complex robotic cardiac surgeries performed with the SSI Mantra \* Some Instruments are currently under development and will be available in the future 13© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_014.jpg)

Advanced Surgical Robotics Technology Platform SSi Maya – Enhancing Surgical Capabilities with Mixed Reality and AI Enabled Technologies SSi Guru XR Tele Proctoring System • Mixed Reality Headset • Portable 3D Surgery Viewer • Interactive Virtual Screens • CDSCO Approved • Virtual Tele Illustration Feature • Proctored over 1200 miles under 400 ms latency AR Smart Glasses\* 3D Visualization System • 3D HD 1080p vision • Variable IPD adjustments • Direct from endoscope video signal processing • IMU based head tracking Cognitive Skill Simulator\* A different approach to train surgeons • Overlaid instruments tracking • Guided procedure steps • Trains cognition and muscle memory • Enhancing motor skills through repetition • Console and VR based learning system Mixed reality - powered and AI - enabled technologies for better training, visualization, and simulation for the entire surgical team. \* Under Development 14© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_015.jpg)

Feb 2025 - SSI HQ – Gurugram, India Manipal Hospital – Jaipur, India 177 miles Mar 2025 - SSI HQ – Gurugram, India Aster CMI Hospital – Bengaluru, India 1,245 miles 15© 2025 SS INNOVATIONS INTERNATIONAL, INC. Advanced Surgical Robotics Technology Platform World's First Robotic Cardiac Tele Surgery

![](ex99-1_016.jpg)

Advanced Surgical Robotics Technology Platform SSI Mantra M – Tele Surgery Mobile Unit Decentralizing and Democratizing access to Robotic surgery to global communities Enhances remote surgical access and empowers underserved communities through tele - surgery, surgical education, mentoring, and real - time data insights. Equipped with the SSI Mantra 3 Surgical Robotic System and MantraSync Tele - Surgery platform Unveiled at the Second Global SS Innovations Multi - Speciality Robotic Surgery Conference 2025, on March 8 th in India \* Under Development 16© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_017.jpg)

Advanced Surgical Robotics Technology Platform SSI Sutra – Centralized Data Registry System Centralized digital platform designed to document, analyze, and streamline surgical workflows, clinical data, and procedural insights across the SSI Mantra robotic ecosystem. \* Under Development 17© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_018.jpg)

Differentiated Product Offering, Including Optimal Cost - Effectiveness and Cardiac Surgery Capabilities SS Innovations Advantages versus Leading Brand 18© 2025 SS INNOVATIONS INTERNATIONAL, INC. Leading Brand SSII Benefit Feature Surgeon Command Center No Yes Ergonomic posture optimizes surgeon comfort and performance Open Face Console No Yes High resolution 3D video for accurate depth perception Large 3D 4K Monitor No Yes Large secondary visual interface to access system controls and data Large 2D Touch Controls Monitor No Yes Open console feature enables clear visibility of physical controls for better precision Hand and Foot Controls Visibility No Yes Better communication with support staff and patient access Instant Operating Room Visibility No Yes Newer technology with completely free range of motions without mechanical restrictions Lightweight Magnetic, Ergonomic Hand Controls No Yes Disables system controls when surgeon disengages hand controls Hand Controls Safety Patient Side Console No Yes Ease of multi - quadrant accessibility Modular Carts No Yes Enabling instrumentation for surgeon's use in complex cases (cardiac) 5 Arm System No Yes Use of 3 - 5 arms based on surgical and cost requirements Robotic Arm Configuration Flexibility Vision Cart No Yes High resolution 3D video for accurate depth perception for surgical assistance Large 3D 4K Monitor for Staff No Yes Records intra - operative surgery videos for data analysis and training In - Built Recording System No Yes Reduces the need for multiple rigid endoscopes Articulating 3D Endoscope Instruments No Yes Instrument used for beating heart totally endoscopic coronary artery bypass surgeries Cardiac Stabilizer No Yes Wristed and cost effective Articulating Reusable Vessel Sealer Enabling Technologies No Yes Enabling true remote access surgery to provide gold - standard robotic surgery from experts Tele - Surgery No Yes Enabling mixed reality technologies to visualize patient data 3D XR DICOM Other No Yes Approximately 1/3rd the cost of competing systems Relative Cost Effectiveness Limited Yes Full spectrum robotic cardiac surgery, including beating heart TECAB with SSI stabilizer Cardiac Surgery Capabilities

![](ex99-1_019.jpg)

Large and Growing Addressable Market with Favorable Industry Tailwinds Market Expected to Increase from $5.1 Billion in 2024 with a CAGR of 11.7% to $15.5 Billion in 2034 1 No. of Multiport Surgical Robotic Systems Geography 6000+ North America 120+ South America 1500+ Europe 570+ Japan 350+ China 290+ India 70+ Australia 10+ Africa 50+ Middle East Largest Market Fastest Growing Market 5.12 15.52 2024 19© 2025 SS INNOVATIONS INTERNATIONAL, INC. 1. https:// www.factmr.com/report/robotic - surgery - market 2034 US$ Billions

![](ex99-1_020.jpg)

Large and Growing Addressable Market with Favorable Industry Tailwinds Accelerated Global Adoption of Robotic Surgery Macro Trends • Large under - penetrated markets such as India, China, and other high - growth economies with rising incomes • Increase in healthcare spending and health insurance in under - penetrated markets Technology Innovation and enhanced capabilities make next - generation systems versatile across a broad spectrum of surgeries Demographics Aging global population driving increased need for surgical interventions Disease Burden Growing incidence of chronic and lifestyle diseases Workforce Challenges Helps address Increasing shortage of trained healthcare workers, by reducing labor intensity across each care episode Economics Improved economics for providers and payers Patient Benefits Reduced patient trauma, shorter recovery times, and enhanced patient outcomes Surgeon Benefits Ergonomic systems reduce staff fatigue and enhanced training pathways across varying skill level improves adoption Hospital Benefits Improved resource utilization, increased revenue, reduced cost with lower complication rates and shorter lengths of stay 5.5 11.1 8.8 25 20 15 10 5 0 2020 2023 2024 2029 US$ Billions Global Surgical Robotics Market\* 23.7 1.6 6.2 8 6 4 2 0 2020 2030 Surgery in Millions Surgeries Conducted by Robotic Systems is Expected to Grow 4x by 2030 SSI aims to accelerate access to surgical robotics in underserved regions of the world 20© 2025 SS INNOVATIONS INTERNATIONAL, INC. https:// www.marketsandmarkets.com/Market - Reports/surgical - robots - market - 256618532.html

![](ex99-1_021.jpg)

Large and Growing Addressable Market with Favorable Industry Tailwinds Access to Robotic Surgery Remains Limited Benefits of Robotic Surgery In the 20 Years Since Launch of Robotic Surgery, Access Remains Limited: Installed base largely limited to the US, EU and Japan 7 billion people have access to only 5% of installed systems Intuitive Surgical has ~10% of the global soft tissue procedure market Key Challenges of Existing Systems High cost of acquisition and implementation Unattractive economics for hospitals with lower volumes Absence of trained personnel Lack of versatility and adaptability of systems and limited systems with multi - specialty capabilities Key Population and Healthcare Data Share of Da Vinci Systems No. of Hospital Beds (thousands) No. of Hospitals Share of Population 59.4% 917 6,120 4.2% USA 18.8% 2,300 15,000 5.6% EU 4.0% 8,000 36,570 17.7% China 1.6% 1,858 70,000 17.8% India 16.2% 4,925 37,310 54.7% RoW Source: Secondary Market Research Greater Precision Minimal Blood Loss Faster Recovery 10x Magnified 3D vision Less Pain and Discomfort Reduced Surgeon Fatigue Smaller Incisions on Patients Reduced Risk of Infection 21© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_022.jpg)© 2025 SS INNOVATIONS INTERNATIONAL, INC. 22 Large and Growing Addressable Market with Favorable Industry Tailwinds Unmet Needs and Accessibility Challenges Support Our Foundational Market in India ~ 60,000 Robot Assisted Surgeries have been performed in India as of 2024 Since 2002, Only 296 Surgical Robotic Systems \* for a population of 1.458 billion ~ 1500 Trained Robotic Surgeons in India ~ 70,000 Hospitals in India ~1.9 Million Beds 700+ Medical Colleges ~26,000 Large Hospitals With 150+ beds ~1.4 Billion Population 93 Surgical Robotic Systems are SSI Mantra (1/3 rd the Installation base) 4,000+ Robot Assisted Surgeries performed in India as of May 2025 on the SSI Mantra 700+ Robotic Surgeons trained on the SSI Mantra Of which \* Source : Independent Market Research Estimated data up to March 31, 2025, except for surgeries and systems installed, which are as of June 2025

![](ex99-1_023.jpg)© 2025 SS INNOVATIONS INTERNATIONAL, INC. 23 World - Class R&D and Manufacturing Facilities to Support Growth Cost - Effective, State - of - the - Art R&D and Manufacturing Facilities in India R&D, Manufacturing, Assembly, and Operations in Gurgaon, Delhi National Capital Region (India) Proximity to New Delhi International airport with excellent connectivity with all parts of the world 75,000 Sq ft space spread over three floors 20 Systems per month Current Production Capacity Manpower as of 4/15/25: 378 Manufacturing expansion plans with inhouse CNC and Tooling machines Data as of March 27, 2025, unless noted otherwise

![](ex99-1_024.jpg)© 2025 SS INNOVATIONS INTERNATIONAL, INC. 24 Stronghold in India, Global Expansion Underway with Near - Term Catalysts Anticipated in the EU and US SS Innovations vs Competitor Installations in India\* Launch Date Company August 2022 SS Innovations September 2021 Medtronic October 2019 CMR December 2002 Intuitive 45 3 2 47 System Installations in 2024 Intuitive CMR Medtronic SSi \* Source : Independent Market Research Estimated data up to March 31, 2025 192 8 41 80 0 50 100 150 200 250 Cumulative System Installations in India (as of March 31, 2025)

![](ex99-1_025.jpg)

Stronghold in India, Global Expansion Underway with Near - Term Catalysts Anticipated in the EU and US Global Expansion - Quality and Regulatory Approvals India CDSCO Nepal Ecuador Guatemala Philippines Indonesia Ukraine Colombia Sri Lanka US FDA EU CE EN ISO 13485 In 2024, SS Innovations generated approximately 92% of its revenue from India . We expect the percent of total revenue coming from the rest of the world to significantly expand from 8% in 2024. 25© 2025 SS INNOVATIONS INTERNATIONAL, INC.

![](ex99-1_026.jpg)

Stronghold in India, Global Expansion Underway with Near - Term Catalysts Anticipated in the EU and US EU CE Mark - Estimated Timeline Route of conformity to Notified body Certification EN ISO 13485 Completed Stage 1 Audit Desktop April 2025 Stage 2 Audit On Site June 2025 CE Marking Nov/Dec 2025\* Initial Review - Application and Technical File March 2025 Notified body - Szutest, Germany Current Stage 26© 2025 SS INNOVATIONS INTERNATIONAL, INC. \* Dependent on the outcome of the review process

![](ex99-1_027.jpg)© 2025 SS INNOVATIONS INTERNATIONAL, INC. 27 Stronghold in India, Global Expansion Underway with Near - Term Catalysts Anticipated in the EU and US US FDA – Estimated Timeline FDA Q Sub Regulatory Strategy Feedback, Biocompatibility, Reprocessing 2024 Current Stage De Novo Classification Request dossier preparation\* De Novo Submission July 2025 Market Clearance Mar/April 2026\*\*\* De Novo Initial Feedback (Deficiency letter) 30 Days \* Animal Acute and Chronic Studies, Human factor validation in the US, Retrospective study (Real world evidence), Cybersecurity \*\* The clinical trial protocols have been drafted if additional trials are required by the US - FDA \*\*\* Dependent on the outcome of the review process Clinical Trials US/ OUS\*\*

![](ex99-1_028.jpg)© 2025 SS INNOVATIONS INTERNATIONAL, INC. 28 Early Innings of Exponential Sales Growth, Expanding Margins and Increasing Mix of Recurring Revenue $5.9 $20.6 2023 2024 Annual Revenue ($ millions) Gross Margin (%) Recurring Revenue 1 (%) 12.35% 40.93% 2023 2024 94% 6% $20.6 mm Revenue 2024 Systems/Other Recurring 1 Recurring revenues from sales of instruments, accessories and services.

![](ex99-1_029.jpg)

Strategy to Deliver Long - Term, Sustainable Growth Emphasis on Organic Growth 29© 2025 SS INNOVATIONS INTERNATIONAL, INC. Continuously Improve and Innovate Our Top - Tier Robotics Platform through New Product Development and Enhanced Technology . Maintain Stronghold in India , Grow in Select Underserved Countries with Low Penetration and Cost Barriers, and Pursue Established Markets . Focus on Large Multi - Specialty Hospitals • Secure Initial Placements • Expand # of Physicians using Mantra 3 • Increase System Utilization at Each Hospital • Place Additional Systems at Each Hospital (Go Deeper) Target Leading Surgeons and Thought Leaders to Raise Awareness and Encourage Widespread Adoption • Indian Medical Advisory Board • International Advisory Board • Medical Conferences • Robotic Surgery Training Programs • Strategic Partners (e.g., Johns Hopkins) Communicate Benefits • Advanced Technology • Low Cost • Ease of Training • Improved Patient Outcomes • Differentiated Features (e.g., Cardiac)

![](ex99-1_030.jpg)

Conclusions 30© 2025 SS INNOVATIONS INTERNATIONAL, INC. • Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology • Advanced, Surgical Robotics Technology Platform Validated Clinically and Commercially • Differentiated Product Offering , Including Optimal Cost - Effectiveness and Cardiac Surgery Capabilities • Large and Growing Addressable Market with Favorable Industry Tailwinds • World - Class R&D and Manufacturing Facilities to Support Growth • Stronghold in India, Global Expansion Underway with Near - Term Catalysts Anticipated in the EU and US • Early Innings of Exponential Sales Growth, Expanding Margins and Increasing Mix of Recurring Revenue • Strategy to Deliver Long - Term, Sustainable Growth

![](ex99-1_031.jpg)

Financial Summary 31© 2025 SS INNOVATIONS INTERNATIONAL, INC. Three Months Ended Twelve Months Ended SS Innovations March 31, 2025 March 31, 2024 December 31, 2024 December 31, 2023 Statement of Operations 5,120,610 3,637,693 20,649,528 5,875,314 Revenue 1,087,208 728,182 8,452,366 725,528 Gross Profit 21.2% 20.0% 40.9% 12.3% Gross margin (5,921,853) (9,832,319) (18,975,962) (20,273,984) Operating income (loss) (5,681,353) (9,841,753) (19,151,197) (20,878,292) Net income (loss) $(0.03) $(0.06) $(0.11) $(0.14) Diluted EPS 188,599,859 181,609,691 181,203,673 152,069,825 Diluted shares March 31, 2025 Balance Sheet 15,873,217 Cash 47,619,943 Current assets 63,456,961 Total assets 14,996,713 Current liabilities - Long term debt 40,554,290 Total stockholders' equity

![](ex99-1_032.jpg)

www.ssinnovations.com investors@ssinnovations.org Investor Contact: Kalle Ahl, CFA (303) 953 - 9878 kahl@theequitygroup.com 32© 2025 SS INNOVATIONS INTERNATIONAL, INC.